Filing Details

Accession Number:
0001209191-21-056530
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-09-17 08:52:04
Reporting Period:
2021-09-15
Accepted Time:
2021-09-17 08:52:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1347178 Vanda Pharmaceuticals Inc. VNDA Pharmaceutical Preparations (2834) 030491827
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1785894 Ii Aranthan Jones C/O Vanda Pharmaceuticals Inc.
2200 Pennsylvania Avenue, Suite 300E
Washington DC 20037
Chief Corp. Affairs Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-09-15 4,277 $12.27 90,962 No 4 M Direct
Common Stock Acquisiton 2021-09-15 7,842 $11.32 98,804 No 4 M Direct
Common Stock Disposition 2021-09-15 16,824 $16.49 81,980 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2021-09-15 4,277 $0.00 4,277 $12.27
Common Stock Employee Stock Option (Right to Buy) Disposition 2021-09-15 7,842 $0.00 7,842 $11.32
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
33,224 2029-07-24 No 4 M Direct
47,158 2030-02-25 No 4 M Direct
Footnotes
  1. A portion of the shares was sold to satisfy the exercise price and tax obligations relating to the acquisition of the shares in connection with the stock option exercise.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.40 to $16.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
  3. The option vested with respect to 25% of the underlying shares on July 25, 2020, with the remaining 75% of the shares vesting in 36 equal monthly installments beginning August 25, 2020, provided the Reporting Person remains continuously employed by the Issuer through each monthly vesting date.
  4. The option vested with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person remains continuously employed by the Issuer through the applicable vesting date.